Artigos de revistas sobre o tema "Irreversible inhibitor"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Irreversible inhibitor".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Buneeva, O. A., L. N. Aksenova e A. E. Medvedev. "A Simple Approach for Pilot Analysis of Time-dependent Enzyme Inhibition: Discrimination Between Mechanism-based Inactivation and Tight Binding Inhibitor Behavior". Biomedical Chemistry: Research and Methods 3, n.º 1 (2020): e00115. http://dx.doi.org/10.18097/bmcrm00115.
Texto completo da fonteGledhill, L., P. Williams e B. W. Bycroft. "Irreversible inactivation of β-lactamase I from Bacillus cereus by chlorinated 6-spiroepoxypenicillins". Biochemical Journal 276, n.º 3 (15 de junho de 1991): 801–7. http://dx.doi.org/10.1042/bj2760801.
Texto completo da fonteRožman, Kaja, Evan M. Alexander, Eva Ogorevc, Krištof Bozovičar, Izidor Sosič, Courtney C. Aldrich e Stanislav Gobec. "Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome". Molecules 25, n.º 6 (12 de março de 2020): 1305. http://dx.doi.org/10.3390/molecules25061305.
Texto completo da fonteMorgan, Hugh P., Martin J. Walsh, Elizabeth A. Blackburn, Martin A. Wear, Matthew B. Boxer, Min Shen, Henrike Veith et al. "A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase". Biochemical Journal 448, n.º 1 (18 de outubro de 2012): 67–72. http://dx.doi.org/10.1042/bj20121014.
Texto completo da fonteVerdugo, Anael, P. K. Vinod, John J. Tyson e Bela Novak. "Molecular mechanisms creating bistable switches at cell cycle transitions". Open Biology 3, n.º 3 (março de 2013): 120179. http://dx.doi.org/10.1098/rsob.120179.
Texto completo da fonteViczjan, Gabor, Tamas Erdei, Ignac Ovari, Nora Lampe, Reka Szekeres, Mariann Bombicz, Barbara Takacs et al. "A Body of Circumstantial Evidence for the Irreversible Ectonucleotidase Inhibitory Action of FSCPX, an Agent Known as a Selective Irreversible A1 Adenosine Receptor Antagonist So Far". International Journal of Molecular Sciences 22, n.º 18 (11 de setembro de 2021): 9831. http://dx.doi.org/10.3390/ijms22189831.
Texto completo da fonteKondža, Martin, Mirza Bojić, Ivona Tomić, Željan Maleš, Valentina Rezić e Ivan Ćavar. "Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids". Molecules 26, n.º 10 (19 de maio de 2021): 3018. http://dx.doi.org/10.3390/molecules26103018.
Texto completo da fonteEspín, J. C., e J. Tudela. "Experimental approach to the kinetic study of unstable site-directed irreversible inhibitors: kinetic origin of the apparent positive co-operativity arising from inactivation of trypsin by p-amidinophenylmethanesulphonyl fluoride". Biochemical Journal 299, n.º 1 (1 de abril de 1994): 29–35. http://dx.doi.org/10.1042/bj2990029.
Texto completo da fonteBitonti, A. J., P. J. Casara, P. P. McCann e P. Bey. "Catalytic irreversible inhibition of bacterial and plant arginine decarboxylase activities by novel substrate and product analogues". Biochemical Journal 242, n.º 1 (15 de fevereiro de 1987): 69–74. http://dx.doi.org/10.1042/bj2420069.
Texto completo da fonteLiyanage, Piyumi Dinusha, Pabudi Weerathunge, Mandeep Singh, Vipul Bansal e Rajesh Ramanathan. "L-Cysteine as an Irreversible Inhibitor of the Peroxidase-Mimic Catalytic Activity of 2-Dimensional Ni-Based Nanozymes". Nanomaterials 11, n.º 5 (13 de maio de 2021): 1285. http://dx.doi.org/10.3390/nano11051285.
Texto completo da fonteMay, Earl, Daniel Urul, Khanh Huynh, Susan Cornell-Kennon, Venkatesh Nemmara, Zhibing Lu, Samuel Hoare, Michelle Lyles e Erik Schaefer. "Abstract 2061: A proven activity-based workflow for the identification and characterization of time-dependent kinase inhibitors using a continuous assay format". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 2061. http://dx.doi.org/10.1158/1538-7445.am2024-2061.
Texto completo da fonteHan, Chun, Jiahong Ren, Feng Su, Xiaoqin Hu, Mengyao Li, Zhijun Wang e Lintao Wu. "Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines". Anti-Cancer Agents in Medicinal Chemistry 20, n.º 6 (14 de junho de 2020): 724–33. http://dx.doi.org/10.2174/1871520620666200302113206.
Texto completo da fonteTikhonova, O. V., V. S. Skvortsov e O. A. Raevsky. "Molecular modeling of acetylcholinesterase interaction with irreversible and reversible organophosphorous inhibitors". Biomeditsinskaya Khimiya 57, n.º 1 (janeiro de 2011): 61–76. http://dx.doi.org/10.18097/pbmc20115701061.
Texto completo da fontePoole, R. C., e A. P. Halestrap. "Reversible and irreversible inhibition, by stilbenedisulphonates, of lactate transport into rat erythrocytes. Identification of some new high-affinity inhibitors". Biochemical Journal 275, n.º 2 (15 de abril de 1991): 307–12. http://dx.doi.org/10.1042/bj2750307.
Texto completo da fonteYu, Xiangfan, Simei Qiu, Dongshan Sun, Pei Guo e Quhuan Li. "Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations". Molecules 27, n.º 21 (2 de novembro de 2022): 7451. http://dx.doi.org/10.3390/molecules27217451.
Texto completo da fonteBastlein, C., e G. Burckhardt. "Sensitivity of rat renal luminal and contraluminal sulfate transport systems to DIDS". American Journal of Physiology-Renal Physiology 250, n.º 2 (1 de fevereiro de 1986): F226—F234. http://dx.doi.org/10.1152/ajprenal.1986.250.2.f226.
Texto completo da fonteKETTLE, Anthony J., Craig A. GEDYE e Christine C. WINTERBOURN. "Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide". Biochemical Journal 321, n.º 2 (15 de janeiro de 1997): 503–8. http://dx.doi.org/10.1042/bj3210503.
Texto completo da fonteRobak, Ewa, e Tadeusz Robak. "Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives". Journal of Clinical Medicine 11, n.º 10 (16 de maio de 2022): 2807. http://dx.doi.org/10.3390/jcm11102807.
Texto completo da fonteWILLIAMS, CARVELL H., e BRENDA BELSHAW. "An iodinated, irreversible inhibitor of monoamine oxidase". Biochemical Society Transactions 13, n.º 2 (1 de abril de 1985): 469–70. http://dx.doi.org/10.1042/bst0130469.
Texto completo da fonteKindler, Hedy L., e Richard L. Schilsky. "Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase". Expert Opinion on Investigational Drugs 9, n.º 7 (julho de 2000): 1635–49. http://dx.doi.org/10.1517/13543784.9.7.1635.
Texto completo da fonteSchaschke, Norbert, Dominga Deluca, Irmgard Assfalg-Machleidt, Clara Höhneke, Christian P. Sommerhoff e Werner Machleidt. "Epoxysuccinyl Peptide-Derived Cathepsin B Inhibitors: Modulating Membrane Permeability by Conjugation with the C-Terminal Heptapeptide Segment of Penetratin". Biological Chemistry 383, n.º 5 (15 de maio de 2002): 849–52. http://dx.doi.org/10.1515/bc.2002.090.
Texto completo da fonteTipton, K. F., J. M. McCrodden e M. B. Youdim. "Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)". Biochemical Journal 240, n.º 2 (1 de dezembro de 1986): 379–83. http://dx.doi.org/10.1042/bj2400379.
Texto completo da fonteGreenspan, M. D., H. G. Bull, J. B. Yudkovitz, D. P. Hanf e A. W. Alberts. "Inhibition of 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis by β-lactone inhibitors and binding of these inhibitors to the enzyme". Biochemical Journal 289, n.º 3 (1 de fevereiro de 1993): 889–95. http://dx.doi.org/10.1042/bj2890889.
Texto completo da fonteRobak, Tadeusz, Magda Witkowska e Piotr Smolewski. "The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions". Cancers 14, n.º 3 (2 de fevereiro de 2022): 771. http://dx.doi.org/10.3390/cancers14030771.
Texto completo da fonteLaw, Brian, Daniel Lu, Priyanka Somanath, James T. Palmer, Taisei Kinoshita e Thomas Butler. "Abstract 2665: Irreversible menin inhibitor, BMF-219, inhibits the growth of KRAS-mutated solid tumors". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 2665. http://dx.doi.org/10.1158/1538-7445.am2022-2665.
Texto completo da fonteBridges, A. J. "The Rationale and Strategy Used to Develop a Series of Highly Potent, Irreversible, Inhibitors of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases". Current Medicinal Chemistry 6, n.º 9 (setembro de 1999): 825–43. http://dx.doi.org/10.2174/092986730609220401151141.
Texto completo da fonteHashimoto, Yoshitami, e Hirofumi Tanaka. "Mre11 exonuclease activity promotes irreversible mitotic progression under replication stress". Life Science Alliance 5, n.º 6 (15 de março de 2022): e202101249. http://dx.doi.org/10.26508/lsa.202101249.
Texto completo da fonteNakatani, Toshiyuki, Ken Uda, Takeshi Yamaura, Masaru Takasaki, Akimi Akashi, Fangli Chen, Yuichi Ishikawa et al. "Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations". Blood 126, n.º 23 (3 de dezembro de 2015): 1353. http://dx.doi.org/10.1182/blood.v126.23.1353.1353.
Texto completo da fonteBoudier, C., e J. G. Bieth. "Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor". Biochemical Journal 303, n.º 1 (1 de outubro de 1994): 61–68. http://dx.doi.org/10.1042/bj3030061.
Texto completo da fonteLombardi, Paolo. "The Irreversible Inhibition of Aromatase (Oestrogen Synthetase) by Steroidal Compounds". Current Pharmaceutical Design 1, n.º 1 (junho de 1995): 23–50. http://dx.doi.org/10.2174/1381612801666220524190226.
Texto completo da fonteGantt, Soren M., Joon Mo Myung, Marcelo R. S. Briones, Wei Dong Li, E. J. Corey, Satoshi Omura, Victor Nussenzweig e Photini Sinnis. "Proteasome Inhibitors Block Development ofPlasmodium spp". Antimicrobial Agents and Chemotherapy 42, n.º 10 (1 de outubro de 1998): 2731–38. http://dx.doi.org/10.1128/aac.42.10.2731.
Texto completo da fonteZeng, Qingbei, Anilkumar G. Nair, Stuart B. Rosenblum, Hsueh-Cheng Huang, Charles A. Lesburg, Yueheng Jiang, Oleg Selyutin et al. "Discovery of an irreversible HCV NS5B polymerase inhibitor". Bioorganic & Medicinal Chemistry Letters 23, n.º 24 (dezembro de 2013): 6585–87. http://dx.doi.org/10.1016/j.bmcl.2013.10.060.
Texto completo da fonteLawyer, Arthur L., Sarita R. Kelley e Judith I. Allen. "Use of Pyruvate-Phosphate Dikinase as a Target for Herbicide Design: Analysis of Inhibitor Specificity". Zeitschrift für Naturforschung C 42, n.º 6 (1 de junho de 1987): 834–36. http://dx.doi.org/10.1515/znc-1987-0633.
Texto completo da fonteLawyer, Arthur L., Sarita R. Kelley e Judith I. Allen. "Use of Pyruvate-Phosphate Dikinase as a Target for Herbicide Design: Analysis of Inhibitor Specificity". Zeitschrift für Naturforschung C 42, n.º 7-8 (1 de agosto de 1987): 834–36. http://dx.doi.org/10.1515/znc-1987-7-816.
Texto completo da fonteBarrand, M. A., e B. A. Callingham. "The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Its use as a radioactive ligand for the enzyme". Biochemical Journal 232, n.º 2 (1 de dezembro de 1985): 415–23. http://dx.doi.org/10.1042/bj2320415.
Texto completo da fonteMaryška, Michal, Lucie Svobodová, Wim Dehaen, Martina Hrabinová, Michaela Rumlová, Ondřej Soukup e Martin Kuchař. "Heterocyclic Cathinones as Inhibitors of Kynurenine Aminotransferase II—Design, Synthesis, and Evaluation". Pharmaceuticals 14, n.º 12 (10 de dezembro de 2021): 1291. http://dx.doi.org/10.3390/ph14121291.
Texto completo da fonteZhang, Datong, He Gong e Fancui Meng. "Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases". Molecules 26, n.º 16 (13 de agosto de 2021): 4907. http://dx.doi.org/10.3390/molecules26164907.
Texto completo da fonteHopkins, Michael, John J. Tyson e Béla Novák. "Cell-cycle transitions: a common role for stoichiometric inhibitors". Molecular Biology of the Cell 28, n.º 23 (7 de novembro de 2017): 3437–46. http://dx.doi.org/10.1091/mbc.e17-06-0349.
Texto completo da fonteLee, Eun, Hyewon Cho, Da Kyung Lee, JuHyun Ha, Byeong Jo Choi, Ji Hye Jeong, Jae-Ha Ryu, Jong Soon Kang e Raok Jeon. "Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase". International Journal of Molecular Sciences 21, n.º 21 (28 de outubro de 2020): 8006. http://dx.doi.org/10.3390/ijms21218006.
Texto completo da fonteBrullo, Chiara, Carla Villa, Bruno Tasso, Eleonora Russo e Andrea Spallarossa. "Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective". International Journal of Molecular Sciences 22, n.º 14 (16 de julho de 2021): 7641. http://dx.doi.org/10.3390/ijms22147641.
Texto completo da fonteHe, Ran, Kyoungsook Park, Hongyi Cai, Arun Kapoor, Michael Forman, Bryan Mott, Gary H. Posner e Ravit Arav-Boger. "Artemisinin-Derived Dimer Diphenyl Phosphate Is an Irreversible Inhibitor of Human Cytomegalovirus Replication". Antimicrobial Agents and Chemotherapy 56, n.º 7 (30 de abril de 2012): 3508–15. http://dx.doi.org/10.1128/aac.00519-12.
Texto completo da fontePenning, T. M. "Irreversible inhibition of Δ5-3-oxosteroid isomerase by 2-substituted progesterones". Biochemical Journal 226, n.º 2 (1 de março de 1985): 469–76. http://dx.doi.org/10.1042/bj2260469.
Texto completo da fontePark, Jong-Hyun, Yeon Ha Ju, Ji Won Choi, Hyo Jung Song, Bo Ko Jang, Junsung Woo, Heejung Chun et al. "Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease". Science Advances 5, n.º 3 (março de 2019): eaav0316. http://dx.doi.org/10.1126/sciadv.aav0316.
Texto completo da fonteSteverding, Dietmar. "On the Reversible and Irreversible Inhibition of Rhodesain by Curcumin". Molecules 25, n.º 1 (30 de dezembro de 2019): 143. http://dx.doi.org/10.3390/molecules25010143.
Texto completo da fonteLighezan, Rodica, Adrian Sturza, Oana M. Duicu, Raluca A. Ceausu, Adrian Vaduva, Marian Gaspar, Horea Feier et al. "Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease". Canadian Journal of Physiology and Pharmacology 94, n.º 10 (outubro de 2016): 1040–47. http://dx.doi.org/10.1139/cjpp-2015-0580.
Texto completo da fonteSchröder, Martin, Panagis Filippakopoulos, Martin P. Schwalm, Carla A. Ferrer, David H. Drewry, Stefan Knapp e Apirat Chaikuad. "Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3". International Journal of Molecular Sciences 21, n.º 21 (26 de outubro de 2020): 7953. http://dx.doi.org/10.3390/ijms21217953.
Texto completo da fonteHarris, Christopher M., Sage E. Foley, Eric R. Goedken, Mark Michalak, Sara Murdock e Noel S. Wilson. "Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase". SLAS DISCOVERY: Advancing the Science of Drug Discovery 23, n.º 10 (10 de julho de 2018): 1040–50. http://dx.doi.org/10.1177/2472555218787445.
Texto completo da fonteKuhn, Deborah J., Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fred W. van Leeuwen e Robert Z. Orlowski. "The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance." Blood 108, n.º 11 (16 de novembro de 2006): 3461. http://dx.doi.org/10.1182/blood.v108.11.3461.3461.
Texto completo da fonteChung, Vincent, Ling Wang, Margaret S. Fletcher, Erminia Massarelli, Karen L. Reckamp, Mihaela C. Cristea, Nikeeta Prajapati et al. "First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): TPS3146. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps3146.
Texto completo da fonteLiclican, Albert, Weimei Xing, Loredana Serafini, Ting Wang, Kathy Brendza, Justin Lutz, Adrian S. Ray, Brian Schultz, Roman Sakowicz e Joy Y. Feng. "Biochemical Characterization of GS-4059 As a Potent and Selective Covalent Irreversible Inhibitor of Bruton's Tyrosine Kinase". Blood 128, n.º 22 (2 de dezembro de 2016): 1594. http://dx.doi.org/10.1182/blood.v128.22.1594.1594.
Texto completo da fonte